Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer()()

BACKGROUND: Paclitaxel is commonly used as first-line chemotherapy for HER2-negative metastatic breast cancer (MBC) patients. However, with response rates of 21.5–53.7% and significant risk of peripheral neuropathy, there is need for better chemotherapy. PATIENTS AND METHODS: This open-label phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahl, Amit, Wilson, William, Ball, Jessica, Renninson, Emily, Dubey, Sidharth, Bravo, Alicia, Foulstone, Emily, Spensley, Saiqa, Bowen, Rebecca, Mansi, Janine, Waters, Simon, Riddle, Pippa, Wheatley, Duncan, Stephens, Peter, Bezecny, Pavel, Madhusudan, Srinivasan, Verrill, Mark, Braybrooke, Jeremy, Comins, Charles, Mohan, Vivek, Gee, Abigail, Kirk, Hannah, Markham, Alison, Evans, Heidi, Watson, Eve, Callaway, Mark, Pearson, Sylvia, Hackshaw, Allan, Churn, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530955/
https://www.ncbi.nlm.nih.gov/pubmed/36194950
http://dx.doi.org/10.1016/j.breast.2022.09.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530955/
https://www.ncbi.nlm.nih.gov/pubmed/36194950
http://dx.doi.org/10.1016/j.breast.2022.09.005

Ejemplares similares